Membranous Nephropathy

1. Overview

Membranous Nephropathy (MN) is the most common cause of nephrotic syndrome in non-diabetic Caucasian adults over 40-60 years of age, representing approximately 25-30% of adult nephrotic syndrome cases in Western populations. [1,2] It is an autoimmune glomerular disease characterized by the deposition of immune complexes on the outer (subepithelial) aspect of the glomerular basement membrane (GBM), leading to complement-mediated podocyte injury, diffuse GBM thickening, and subsequent massive proteinuria.

The seminal discovery of the M-type Phospholipase A2 Receptor (PLA2R) as the target antigen in 2009 revolutionized our understanding of primary MN, transforming it from an idiopathic condition to a well-characterized autoimmune disease. [3] This breakthrough has enabled non-invasive serological diagnosis, accurate disease monitoring, and targeted therapeutic approaches. Approximately 70-80% of primary MN cases are PLA2R-associated, with additional antigens including THSD7A (3-5%), NELL-1, Semaphorin 3B, and others being identified in recent years. [4,5]

The clinical course of untreated MN follows the classical "Rule of Thirds"

• approximately one-third of patients achieve spontaneous remission, one-third maintain stable proteinuria with preserved renal function, and one-third progress to end-stage renal disease (ESRD) over 5-15 years. [6] Modern treatment with B-cell depleting agents, particularly Rituximab, has significantly improved outcomes for patients at moderate-to-high risk of progression.

Key Clinical Features

---

2. Epidemiology

Incidence and Prevalence

Membranous nephropathy has an estimated incidence of 1-1.2 per 100,000 population per year in Western countries, making it one of the most common primary glomerular diseases. [1,2] Prevalence estimates suggest approximately 10-12 cases per 100,000 population.

Age-Specific Considerations

Adults 40-60 years:

• Peak incidence of primary (idiopathic) MN
• PLA2R-associated disease predominates
• Thorough malignancy screening warranted if clinical features suggest secondary cause

Adults > 60 years:

• Higher proportion of secondary MN (up to 20-25%)
• Increased malignancy association (solid tumors: lung, colon, breast, stomach, prostate)
• More aggressive age-appropriate cancer screening required [7]

Young Adults (less than 40 years):

• Consider secondary causes more strongly (SLE, Hepatitis B, drugs)
• May have more aggressive disease course
• THSD7A-associated MN may present in younger patients

Risk Factors

Genetic Susceptibility:

• HLA-DQA1 alleles (particularly HLA-DQA105:01 and DQA106:01) associated with PLA2R-associated MN [8]
• PLA2R1 gene polymorphisms (SNPs) increase susceptibility
• Familial clustering reported but rare

Environmental Factors:

• Hepatitis B infection (especially in endemic regions - Asia, Africa)
• Occupational exposures (hydrocarbons, mercury)
• Certain medications (NSAIDs, penicillamine, gold, captopril, anti-TNF agents)

---

3. Aetiology and Classification

Primary Membranous Nephropathy (70-80%)

Primary MN is an organ-specific autoimmune disease characterized by autoantibodies targeting podocyte antigens. The identification of specific target antigens has transformed classification:

PLA2R-Associated MN (70-80% of Primary Cases)

The M-type Phospholipase A2 Receptor (PLA2R) is a 180-kDa transmembrane glycoprotein expressed on the surface of podocytes. [3] Anti-PLA2R antibodies, predominantly of the IgG4 subclass, target specific conformational epitopes within the cysteine-rich (CysR), fibronectin type II (FNII), and C-type lectin-like domains (CTLD1-8).

Epitope Spreading Phenomenon: Disease typically begins with antibodies targeting the CysR domain, then spreads to FNII and CTLD domains. Patients with antibodies against multiple epitopes (epitope spreading) have more severe disease and worse prognosis. [9]

THSD7A-Associated MN (3-5% of Primary Cases)

Thrombospondin Type-1 Domain-Containing 7A (THSD7A) was identified as the second major podocyte antigen in MN. [5] Key features:

• Present in 3-5% of PLA2R-negative primary MN
• Possible association with malignancy (especially in older patients)
• Patients should undergo thorough malignancy screening
• Predominantly IgG4 antibodies

Other Identified Antigens

Secondary Membranous Nephropathy (20-30%)

Secondary MN occurs when glomerular immune complex deposition results from an identifiable underlying condition. The pathological pattern may be indistinguishable from primary MN, but secondary causes are typically PLA2R-negative.

Major Secondary Causes

Malignancy (5-20% of MN in patients > 60 years): [7]

Autoimmune Diseases:

Infections:

Drug-Induced MN:

Other Associations:

• Sarcoidosis
• Hematopoietic stem cell transplantation (HSCT)
• Graft-versus-host disease (GVHD)
• De novo MN in renal allografts

---

4. Pathophysiology

Molecular Mechanisms

Exam Detail: The pathophysiology of membranous nephropathy represents a paradigm of organ-specific autoimmune disease, with well-characterized molecular mechanisms from autoantibody generation to podocyte injury.

Step 1: Autoantibody Formation

In primary MN, autoreactive B cells produce antibodies against podocyte membrane antigens. The predominant immunoglobulin subclass is IgG4, which has unique properties:

• Does not efficiently activate classical complement pathway
• Can undergo Fab-arm exchange (half-antibody exchange)
• Forms small immune complexes

The trigger for loss of tolerance to PLA2R/THSD7A remains unclear but may involve:

• Genetic susceptibility (HLA associations)
• Environmental triggers (infections, drugs)
• Post-translational modifications of podocyte antigens

Step 2: In Situ Immune Complex Formation

Unlike some immune complex glomerulonephritides where circulating complexes deposit, MN is characterized by in situ immune complex formation:

1. Circulating anti-PLA2R IgG4 antibodies cross the GBM
2. Antibodies bind to PLA2R expressed on the basal surface of podocyte foot processes
3. Antigen-antibody complexes form on the subepithelial (outer) aspect of the GBM
4. GBM material is deposited around and between immune deposits

This subepithelial location distinguishes MN from proliferative glomerulonephritides (subendothelial deposits) and explains the absence of inflammatory cell infiltration.

Step 3: Complement Activation and Podocyte Injury

Despite IgG4 predominance, complement activation occurs through:

• Lectin pathway activation (MBL binds to glycosylated IgG4)
• Alternative pathway amplification
• Minor classical pathway contribution (IgG1-3 present in smaller amounts)

Complement activation leads to assembly of the Membrane Attack Complex (C5b-9) on podocyte membranes. Unlike endothelial cells, podocytes have limited ability to shed or internalize C5b-9, leading to sublytic injury.

C5b-9-Mediated Podocyte Injury:

• Oxidative stress and reactive oxygen species (ROS) generation
• Protease release (cathepsins, metalloproteinases)
• Cytoskeletal disruption (actin reorganization)
• Slit diaphragm protein dysfunction (nephrin, podocin)
• Foot process effacement
• Disrupted podocyte-GBM adhesion

Step 4: Proteinuria Development

Podocyte injury results in breakdown of the glomerular filtration barrier:

• Size-selectivity barrier loss: Large proteins (albumin, immunoglobulins) pass through
• Charge-selectivity barrier loss: Loss of anionic glycocalyx
• Foot process effacement: Loss of slit diaphragm integrity

The result is massive non-selective proteinuria, typically > 3.5 g/day, often exceeding 10 g/day in severe cases.

Step 5: GBM Remodeling

Over time, the GBM responds to persistent subepithelial deposits:

• New GBM material is synthesized between and around deposits
• Creates the characteristic "spike" appearance on silver staining
• Progressive GBM thickening
• Eventually, deposits become incorporated within the thickened GBM
• Late stages show deposit resorption, leaving "moth-eaten" or lucent areas

Pathophysiology Summary Diagram

┌─────────────────────────────────────────────────────────────────────────────────┐
│                    MEMBRANOUS NEPHROPATHY PATHOPHYSIOLOGY                       │
├─────────────────────────────────────────────────────────────────────────────────┤
│                                                                                 │
│   ┌───────────────────────────────────────────────────────────────────────┐     │
│   │                    AUTOANTIBODY GENERATION                            │     │
│   │  • Loss of tolerance to podocyte antigens                             │     │
│   │  • Genetic susceptibility: HLA-DQA1 associations                      │     │
│   │  • Autoreactive B cells → IgG4 anti-PLA2R (70-80%)                    │     │
│   │  • Less common: Anti-THSD7A (3-5%), Anti-NELL-1, others               │     │
│   └───────────────────────────────────────────────────────────────────────┘     │
│                                      ↓                                          │
│   ┌───────────────────────────────────────────────────────────────────────┐     │
│   │                  IN SITU IMMUNE COMPLEX FORMATION                     │     │
│   │  • Antibodies cross GBM and bind antigens ON podocyte surface         │     │
│   │  • Subepithelial immune deposit formation                             │     │
│   │  • NO inflammatory cell recruitment (IgG4 properties)                 │     │
│   └───────────────────────────────────────────────────────────────────────┘     │
│                                      ↓                                          │
│   ┌───────────────────────────────────────────────────────────────────────┐     │
│   │                    COMPLEMENT ACTIVATION                              │     │
│   │  • Lectin pathway (MBL binds glycosylated IgG)                        │     │
│   │  • Alternative pathway amplification                                  │     │
│   │  • Assembly of C5b-9 (Membrane Attack Complex) on podocytes           │     │
│   │  • Sublytic podocyte injury (not cell death)                          │     │
│   └───────────────────────────────────────────────────────────────────────┘     │
│                                      ↓                                          │
│   ┌───────────────────────────────────────────────────────────────────────┐     │
│   │                      PODOCYTE INJURY                                  │     │
│   │  • Oxidative stress and ROS generation                                │     │
│   │  • Protease release (cathepsins, MMPs)                                │     │
│   │  • Cytoskeletal disruption                                            │     │
│   │  • Foot process effacement                                            │     │
│   │  • Slit diaphragm dysfunction (nephrin, podocin)                      │     │
│   └───────────────────────────────────────────────────────────────────────┘     │
│                                      ↓                                          │
│   ┌──────────────────┬───────────────────────┬──────────────────────────┐       │
│   │   MASSIVE        │    GBM THICKENING     │   HYPERCOAGULABILITY     │       │
│   │   PROTEINURIA    │    & REMODELING       │                          │       │
│   │                  │                       │                          │       │
│   │  • > 3.5 g/day    │  • Spike formation    │  • Urinary AT-III loss   │       │
│   │  • Often > 10 g/d │  • Deposit incorp-    │  • Urinary Protein S     │       │
│   │  • Non-selective │    oration            │    loss                  │       │
│   │                  │  • Late: resorption   │  • ↑ Fibrinogen synth    │       │
│   └──────────────────┴───────────────────────┴──────────────────────────┘       │
│                                      ↓                                          │
│   ┌───────────────────────────────────────────────────────────────────────┐     │
│   │                    CLINICAL NEPHROTIC SYNDROME                        │     │
│   │  • Hypoalbuminemia → Edema                                            │     │
│   │  • Hyperlipidemia → Accelerated atherosclerosis                       │     │
│   │  • Hypercoagulability → VTE risk (highest of all GNs)                 │     │
│   │  • Immunoglobulin loss → Infection susceptibility                     │     │
│   └───────────────────────────────────────────────────────────────────────┘     │
│                                                                                 │
└─────────────────────────────────────────────────────────────────────────────────┘

Hypercoagulability in Membranous Nephropathy

MN carries the highest risk of venous thromboembolism (VTE) of all glomerular diseases, with rates of 20-35% reported in various series. Renal vein thrombosis (RVT) occurs in up to 30% of patients with severe nephrotic syndrome. [11]

Mechanisms of Hypercoagulability:

Risk Stratification for VTE:

• Serum albumin less than 20-25 g/L is the primary risk factor
• Proteinuria > 10 g/day
• Recent immobilization or hospitalization
• Prior VTE history
• Obesity (BMI > 35)

---

5. Clinical Presentation

History Taking

Cardinal Symptoms

Edema (Present in 80-90% at diagnosis):

• Usually the presenting complaint
• Typically begins as dependent edema (ankles, legs)
• Progresses to periorbital edema (especially morning)
• May develop anasarca with ascites and pleural effusions in severe cases
• Characterized by pitting quality

Frothy Urine (60-70%):

• Indicates heavy proteinuria
• Patients may describe "foamy" or "bubbly" urine
• Often persists despite flushing

Fatigue and Malaise:

• Often profound and debilitating
• Related to hypoalbuminemia and uremia
• May be the dominant complaint in some patients

Weight Gain:

• Rapid weight gain over days to weeks
• Due to fluid retention
• May be > 5-10 kg in severe cases

Reduced Urine Output:

• May occur in setting of severe hypoalbuminemia
• Can indicate acute kidney injury

Symptoms Suggesting Complications

Screening for Secondary Causes

Red Flags for Malignancy:

• Unintentional weight loss (> 5% in 6 months)
• Night sweats
• Lymphadenopathy
• Change in bowel habits
• Haematuria (gross)
• New persistent cough or haemoptysis
• Age > 60 years (especially if PLA2R-negative)

Red Flags for Autoimmune Disease (SLE):

• Photosensitive rash
• Oral ulcers
• Joint pains (inflammatory pattern)
• Alopecia
• Serositis
• Cytopenias
• Young female patient

Medication History:

• NSAIDs (duration and type)
• Penicillamine, Gold (rheumatoid arthritis treatment)
• Anti-TNF biologics
• Captopril (high-dose historical use)
• Any recent new medications

Infection Risk Factors:

• Hepatitis B risk factors (endemic area, blood transfusion, IVDU, sexual contact)
• Hepatitis C risk factors
• HIV risk factors
• Travel history (malaria, schistosomiasis)

Physical Examination

General Inspection

Cardiovascular Examination

Respiratory Examination

Abdominal Examination

Examination for Secondary Causes

---

6. Investigations

Diagnostic Approach

The investigation of membranous nephropathy involves:

1. Confirming nephrotic syndrome (proteinuria, hypoalbuminemia)
2. Establishing MN diagnosis (anti-PLA2R +/- biopsy)
3. Excluding secondary causes (malignancy, SLE, infections, drugs)
4. Risk stratification for treatment decisions

First-Line Investigations

Urine Investigations

Blood Investigations

Serological Investigations

Anti-PLA2R Antibody Testing

The anti-PLA2R antibody test has transformed the diagnosis of primary MN. [3,12]

Clinical Utility:

1. Diagnosis: A positive anti-PLA2R in a patient with nephrotic syndrome and preserved eGFR may obviate the need for renal biopsy (KDIGO 2021). [1]

2. Prognosis: Higher titers correlate with more severe disease and lower likelihood of spontaneous remission.

3. Monitoring: Titers correlate with disease activity. Immunological remission (antibody disappearance) typically precedes proteinuria remission by 3-12 months.

4. Recurrence prediction: Pre-transplant titers predict recurrence in the renal allograft.

Interpretation:

Anti-THSD7A Antibody Testing

Secondary Cause Screening

Malignancy Screening

Malignancy screening is mandatory in all patients with MN, particularly:

• Age > 60 years
• PLA2R-negative disease
• THSD7A-positive disease
• Clinical features suggesting malignancy (weight loss, lymphadenopathy)

Recommended Screening:

Renal Biopsy

Indications for Renal Biopsy

KDIGO 2021 Recommendations: [1]

Renal biopsy may NOT be required if:

• Anti-PLA2R positive
• Typical nephrotic syndrome presentation
• Preserved eGFR
• No clinical features suggesting secondary cause

Renal biopsy IS indicated if:

• Anti-PLA2R negative
• Rapidly declining eGFR
• Active urinary sediment (haematuria, RBC casts)
• Features suggesting secondary cause (e.g., SLE)
• Failure to respond to treatment
• Atypical clinical presentation

Histopathological Findings

Light Microscopy (LM):

Immunofluorescence (IF):

Electron Microscopy (EM):

Key Point: EM staging does NOT reliably predict outcome or response to therapy.

---

7. Risk Stratification

KDIGO 2021 Risk Categories

Risk stratification guides treatment decisions and is based on proteinuria level, renal function, and anti-PLA2R titer after a period of supportive care. [1]

Prognostic Factors

Favorable Prognosis:

• Low-level proteinuria (less than 4 g/day)
• Normal eGFR at presentation
• Female sex
• Low or absent anti-PLA2R titers
• Negative anti-THSD7A
• Spontaneous decline in proteinuria during observation
• Immunological remission (antibody disappearance) with treatment

Unfavorable Prognosis:

• Heavy proteinuria (> 8 g/day)
• Reduced eGFR at presentation
• Male sex
• Persistent high anti-PLA2R titers
• Epitope spreading (CysR + FNII + CTLD domains)
• Tubulointerstitial fibrosis on biopsy
• No immunological remission with treatment
• Older age

The Rule of Thirds (Natural History)

The classical "Rule of Thirds" describes the untreated natural history of primary MN: [6]

┌─────────────────────────────────────────────────────────────────┐
│                    RULE OF THIRDS PROGNOSIS                      │
├─────────────────────────────────────────────────────────────────┤
│                                                                  │
│   ┌──────────────────────────────────────────────────────────┐  │
│   │           UNTREATED PRIMARY MN (100%)                    │  │
│   └──────────────────────────────────────────────────────────┘  │
│                            │                                     │
│           ┌────────────────┼────────────────┐                   │
│           ↓                ↓                ↓                   │
│   ┌───────────────┐ ┌───────────────┐ ┌───────────────┐        │
│   │  ~33% (1/3)   │ │  ~33% (1/3)   │ │  ~33% (1/3)   │        │
│   │               │ │               │ │               │        │
│   │  SPONTANEOUS  │ │   PERSISTENT  │ │  PROGRESSIVE  │        │
│   │   REMISSION   │ │  PROTEINURIA  │ │   DISEASE     │        │
│   │               │ │               │ │               │        │
│   │ • Complete or │ │ • Stable      │ │ • Declining   │        │
│   │   partial     │ │   proteinuria │ │   eGFR        │        │
│   │   remission   │ │ • Preserved   │ │ • ESRD in     │        │
│   │ • Usually     │ │   eGFR        │ │   5-15 years  │        │
│   │   within      │ │ • Ongoing     │ │ • Requires    │        │
│   │   6-24 months │ │   monitoring  │ │   RRT         │        │
│   └───────────────┘ └───────────────┘ └───────────────┘        │
│                                                                  │
└─────────────────────────────────────────────────────────────────┘

Important Notes:

• This rule applies to untreated patients receiving only supportive care
• Modern immunosuppressive therapy significantly improves outcomes for high-risk patients
• Patients with low-risk disease (proteinuria less than 4 g/day) have > 80% chance of spontaneous remission
• The observation period for spontaneous remission is typically 6-12 months

---

8. Management

Management Algorithm

┌─────────────────────────────────────────────────────────────────────────────────┐
│                    MEMBRANOUS NEPHROPATHY MANAGEMENT ALGORITHM                   │
├─────────────────────────────────────────────────────────────────────────────────┤
│                                                                                 │
│   DIAGNOSIS CONFIRMED (Primary MN with Anti-PLA2R+ or Biopsy-proven)            │
│                                      ↓                                          │
│   ┌───────────────────────────────────────────────────────────────────────┐     │
│   │                  SECONDARY CAUSE EXCLUSION                            │     │
│   │  • Age-appropriate malignancy screening (CT CAP, colonoscopy, etc.)   │     │
│   │  • Review medications (NSAIDs, biologics)                             │     │
│   │  • Autoimmune screen (ANA, dsDNA, complement)                         │     │
│   │  • Infection screen (HBV, HCV, HIV, syphilis)                         │     │
│   └───────────────────────────────────────────────────────────────────────┘     │
│                                      ↓ Negative                                 │
│   ┌───────────────────────────────────────────────────────────────────────┐     │
│   │         INITIATE MAXIMAL SUPPORTIVE CARE (ALL PATIENTS)               │     │
│   │  • ACEi or ARB (titrate to maximal tolerated dose)                    │     │
│   │  • Target BP less than 120/80 mmHg                                             │     │
│   │  • Diuretics for edema (loop ± thiazide)                              │     │
│   │  • Statins for hyperlipidemia                                         │     │
│   │  • Dietary salt restriction (less than 2g/day)                                 │     │
│   │  • Moderate protein intake (0.8-1.0 g/kg/day)                         │     │
│   │  • Consider anticoagulation if albumin less than 20-25 g/L                     │     │
│   └───────────────────────────────────────────────────────────────────────┘     │
│                                      ↓                                          │
│   ┌───────────────────────────────────────────────────────────────────────┐     │
│   │                      RISK STRATIFICATION                              │     │
│   │            (After 3-6 months of supportive care)                      │     │
│   └───────────────────────────────────────────────────────────────────────┘     │
│          ↓                ↓                  ↓                  ↓               │
│   ┌───────────┐    ┌────────────┐     ┌────────────┐    ┌─────────────┐        │
│   │ LOW RISK  │    │ MODERATE   │     │ HIGH RISK  │    │ VERY HIGH   │        │
│   │           │    │ RISK       │     │            │    │ RISK        │        │
│   │ Prot less than 4g  │    │ Prot 4-8g  │     │ Prot > 8g   │    │ Life-threat │        │
│   │ Normal eGFR│   │ Stable eGFR│     │ OR ↓eGFR   │    │ nephrosis   │        │
│   └───────────┘    └────────────┘     └────────────┘    └─────────────┘        │
│          ↓                ↓                  ↓                  ↓               │
│   ┌───────────┐    ┌────────────┐     ┌────────────┐    ┌─────────────┐        │
│   │ CONTINUE  │    │ OBSERVE    │     │  TREAT     │    │ TREAT NOW   │        │
│   │ SUPPORT-  │    │ 3-6 MORE   │     │  NOW       │    │ (URGENT)    │        │
│   │ IVE CARE  │    │ MONTHS     │     │            │    │             │        │
│   │           │    │            │     │            │    │             │        │
│   │ Monitor   │    │ If persists│     │            │    │             │        │
│   │ 6 monthly │    │ → TREAT    │     │            │    │             │        │
│   └───────────┘    └────────────┘     └────────────┘    └─────────────┘        │
│                                              ↓                  ↓               │
│                          ┌─────────────────────────────────────────────┐        │
│                          │          FIRST-LINE IMMUNOSUPPRESSION       │        │
│                          │                                             │        │
│                          │  RITUXIMAB (PREFERRED - KDIGO 2021)         │        │
│                          │  • 1g IV x2 doses (Day 0 and Day 14)        │        │
│                          │  OR                                         │        │
│                          │  • 375 mg/m² weekly x4 doses                │        │
│                          │                                             │        │
│                          │  ALTERNATIVE: Cyclophosphamide-based        │        │
│                          │  (Modified Ponticelli Regimen)              │        │
│                          │  • Higher toxicity but well-established     │        │
│                          └─────────────────────────────────────────────┘        │
│                                              ↓                                  │
│                          ┌─────────────────────────────────────────────┐        │
│                          │              MONITORING                     │        │
│                          │  • Anti-PLA2R titers q3 months              │        │
│                          │  • Proteinuria q1-3 months                  │        │
│                          │  • eGFR q3 months                           │        │
│                          │  • CD19/CD20 counts (if on rituximab)       │        │
│                          └─────────────────────────────────────────────┘        │
│                                                                                 │
└─────────────────────────────────────────────────────────────────────────────────┘

Supportive Care (All Patients)

All patients with MN should receive maximal supportive care, regardless of risk category.

ACE Inhibitors / Angiotensin Receptor Blockers

Goals:

• Reduce proteinuria by 30-50%
• Blood pressure target less than 120/80 mmHg
• Accept up to 30% increase in creatinine (may stabilize)

Cautions:

• Avoid in pregnancy (teratogenic)
• Monitor potassium (risk of hyperkalemia)
• Avoid in bilateral renal artery stenosis

Diuretics

Practical Tips:

• Start with oral furosemide 40-80 mg twice daily
• If poor response, consider IV administration or metolazone addition
• Avoid aggressive diuresis (risk of AKI, thrombosis from hemoconcentration)

Statins

All patients with nephrotic-range proteinuria should receive statin therapy:

• Atorvastatin 10-40 mg daily (first-line)
• Rosuvastatin 5-20 mg daily (alternative)

Rationale: Reduce hyperlipidemia-associated cardiovascular risk and possibly slow progression.

Dietary Modifications

Anticoagulation Therapy

MN carries the highest VTE risk of all glomerular diseases. Prophylactic anticoagulation is controversial but often recommended for high-risk patients. [11]

Indications for Prophylactic Anticoagulation

Anticoagulation Options

Duration: Continue until serum albumin > 30 g/L

KDIGO 2021: "We suggest prophylactic anticoagulation in patients with severe hypoalbuminemia (serum albumin less than 20-25 g/L) and additional VTE risk factors, when the bleeding risk is acceptable." [1]

Immunosuppressive Therapy

Rituximab (First-Line - KDIGO 2021)

Rituximab is a chimeric anti-CD20 monoclonal antibody that depletes B cells. The MENTOR trial established its efficacy in MN. [13]

Dosing Regimens:

Mechanism:

• Depletes CD20+ B cells (including autoreactive B cell clones)
• Reduces anti-PLA2R antibody production
• Effect on proteinuria delayed (months after immunological remission)

Response Assessment:

• Anti-PLA2R titers q3 months
• Complete remission: Proteinuria less than 0.3 g/day
• Partial remission: Proteinuria less than 3.5 g/day with ≥50% reduction from baseline

MENTOR Trial Evidence: [13]

• Randomized controlled trial: Rituximab vs Cyclosporine
• At 12 months: Non-inferior for complete/partial remission (60% vs 52%)
• At 24 months: Superior for sustained remission (60% vs 20%)
• Rituximab preferred due to more durable remissions and better safety

Retreatment:

• Consider repeat dosing if:
  • Rising anti-PLA2R titers after initial remission
  • B cell reconstitution with relapse
  • Incomplete response to initial course

Adverse Effects:

Cyclophosphamide-Based Regimens

Cyclophosphamide combined with corticosteroids (Ponticelli or modified Ponticelli regimen) has the longest evidence base in MN. [14]

Modified Ponticelli Regimen:

Total Cyclophosphamide Exposure: ~180 mg/kg over 3 months

Evidence:

• 10-year follow-up data show excellent long-term renal survival (> 70% dialysis-free)
• More effective than calcineurin inhibitors for preventing ESRD
• Goldstandard for very high-risk patients

Indications for Cyclophosphamide over Rituximab:

• Very high-risk disease (life-threatening nephrotic syndrome, rapid eGFR decline)
• Rituximab failure or intolerance
• Resource-limited settings
• Patient preference

Adverse Effects:

Calcineurin Inhibitors (Second-Line)

Cyclosporine or tacrolimus may be used as second-line agents or in patients intolerant to rituximab/cyclophosphamide.

Limitations:

• High relapse rate upon discontinuation (40-60%)
• Nephrotoxicity (chronic interstitial fibrosis)
• Requires combination with low-dose corticosteroids in some protocols

Role: MENTOR trial showed cyclosporine inferior to rituximab for sustained remission at 24 months. [13]

Other Agents

Treatment Response Monitoring

Definitions of Remission

Monitoring Schedule

Clinical Pearl: Immunological vs Clinical Remission: Anti-PLA2R antibodies typically disappear 3-12 months BEFORE proteinuria remission. Do not escalate or change treatment if anti-PLA2R has normalized but proteinuria persists - the podocytes need time to heal. Continue supportive care and monitor.

---

9. Complications

Disease-Related Complications

Venous Thromboembolism

MN has the highest VTE risk of all nephrotic syndromes. [11]

Management of VTE in MN:

• Therapeutic anticoagulation with LMWH or warfarin (INR 2-3)
• Duration: Until nephrotic syndrome resolves (albumin > 30 g/L) + additional 3-6 months
• DOACs may be considered but limited data in nephrotic syndrome

Infection

Common Infections:

• Spontaneous bacterial peritonitis (with ascites)
• Cellulitis
• Pneumonia (especially Streptococcus pneumoniae)
• UTI

Vaccination Recommendations:

• Pneumococcal vaccine (PCV13 + PPSV23)
• Annual influenza vaccine
• Avoid live vaccines if on immunosuppression

Acute Kidney Injury

Hyperlipidemia and Cardiovascular Disease

• Accelerated atherosclerosis
• Increased cardiovascular events
• Managed with statins

Treatment-Related Complications

---

10. Special Populations

Pregnancy

MN in pregnancy is challenging due to high thrombotic risk and need to avoid teratogenic medications.

Elderly Patients (> 65 years)

Renal Transplantation

Clinical Pearl: Transplant Timing: Consider delaying transplantation until anti-PLA2R antibodies are undetectable to reduce recurrence risk. Monitor anti-PLA2R titers in waitlisted patients.

Secondary MN Management

---

11. Prognosis

Natural History (Untreated)

The "Rule of Thirds" describes outcomes with supportive care only: [6]

Outcomes with Treatment

Modern immunosuppressive therapy has significantly improved outcomes for patients at moderate-to-high risk.

MENTOR Trial (Rituximab vs Cyclosporine): [13]

• Complete or partial remission at 24 months: Rituximab 60% vs Cyclosporine 20%
• Demonstrates durable remission with rituximab

Long-term Cyclophosphamide Data: [14]

• 10-year dialysis-free survival: > 70% in treated patients
• Superior to calcineurin inhibitors for renal survival

Predictors of Outcome

---

12. Key Clinical Pearls

Exam-Focused Points

Exam Detail: 1. Most Common Cause: Primary (idiopathic) MN is the most common cause of nephrotic syndrome in non-diabetic Caucasian adults aged 40-60 years.

2. PLA2R Revolution: Anti-PLA2R antibody is ~70-80% sensitive and > 99% specific for primary MN. A positive result in typical nephrotic syndrome may obviate biopsy (KDIGO 2021).

3. Rule of Thirds: In untreated MN, ~1/3 spontaneously remit, ~1/3 have stable proteinuria with preserved function, and ~1/3 progress to ESRD. This justifies "watch and wait" for low-risk patients.

4. Highest VTE Risk: MN has the highest venous thromboembolism risk of any glomerular disease. Prophylactic anticoagulation is recommended when albumin less than 20-25 g/L and bleeding risk is low.

5. Renal Vein Thrombosis: Suspect RVT in MN patients with new flank pain, haematuria, or worsening renal function. Up to 30% of severe MN patients develop RVT.

6. Secondary Causes: The "6 S's"

• SLE, Solid tumors (malignancy), Syphilis, Sarcoid, and (6th) drugs (NSAIDs, penicillamine, gold, anti-TNF agents). Screen all patients, especially if PLA2R-negative or age > 60.

7. Rituximab First-Line: The MENTOR trial established rituximab as preferred first-line immunosuppression for moderate/high-risk MN due to superior sustained remission rates compared to cyclosporine.

8. Ponticelli Regimen: The classic cyclophosphamide/steroid alternating regimen remains an option for very high-risk disease or rituximab failure.

9. Immunological Remission Precedes Clinical: Anti-PLA2R titers fall before proteinuria improves (by 3-12 months). Don't change treatment if antibodies have normalized but proteinuria persists - podocytes need time to heal.

10. GBM Histology: Classic appearance is "spike and dome" on silver stain (Stage II) representing GBM projections between subepithelial deposits. EM shows subepithelial electron-dense deposits.

Common Exam Scenarios

What Gets You Failed

• Missing secondary cause screening (especially malignancy in elderly)
• Not knowing the role of anti-PLA2R antibody
• Not understanding the rationale for "watch and wait" in low-risk disease
• Confusing subepithelial (MN) with subendothelial (proliferative GN) deposits
• Not knowing thrombotic complications and management
• Recommending cyclophosphamide without discussing toxicity (infertility, malignancy)

---

13. Patient Explanation

What is Membranous Nephropathy?

"Membranous Nephropathy is an autoimmune kidney disease. 'Autoimmune' means your body's immune system mistakenly attacks healthy tissue. In this case, it produces antibodies that attack the tiny filters (called glomeruli) in your kidneys.

This attack damages the filters, causing them to become leaky. Normally, protein stays in your blood, but when the filters are damaged, protein leaks into your urine. This protein loss leads to several problems: fluid builds up in your body (causing swelling), your cholesterol goes up, and your blood becomes more prone to clotting."

What Caused It?

"In about 75% of cases, this happens on its own - we call this 'Primary' Membranous Nephropathy. We can test for a specific antibody called anti-PLA2R that causes this.

In the remaining 25% of cases ('Secondary'), it can be triggered by another condition - sometimes a medication, an infection like Hepatitis B, or occasionally a hidden cancer. This is why we do thorough checks to rule these out, especially in older patients."

Will I Need Dialysis?

"Not necessarily. We follow what we call the 'Rule of Thirds':

• About one-third of patients get better on their own without strong medications
• About one-third stay stable with some protein leakage but keep good kidney function
• About one-third may have worsening kidney function over time

We use blood tests (checking your anti-PLA2R antibody level) and urine tests to determine your risk category. This helps us decide whether you need strong immune-suppressing medication or whether we can safely monitor you with supportive treatments."

Why Do I Need Blood Thinners?

"Because you're losing protein in your urine, you're also losing some of your body's natural blood-thinning proteins. This makes your blood 'stickier' and more likely to form clots. If your albumin level gets very low (below 20-25), we often use blood thinners to prevent dangerous clots in your legs, lungs, or kidney veins."

What Are My Treatment Options?

"We start everyone with basic supportive treatments: blood pressure medications that also protect your kidneys (ACE inhibitors), tablets to reduce swelling (diuretics), and cholesterol-lowering medications.

If your disease is higher risk, we may recommend immune-suppressing treatment. The preferred option now is a medication called Rituximab - it's given as an infusion and works by reducing the cells that make the harmful antibodies. An older alternative involves a combination of steroids and a stronger drug called cyclophosphamide, which is very effective but has more side effects.

The good news is that with modern treatment, most patients with membranous nephropathy can avoid dialysis."

---

14. Evidence and Guidelines

Key Guidelines

Landmark Trials

MENTOR Trial (2019) [13]

GEMRITUX Trial (2017) [16]

Beck et al. (2009) - PLA2R Discovery [3]

Ponticelli et al. - Cyclophosphamide Studies [14]

Evidence-Based Recommendations

---

15. References

1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021

2. Cattran DC, Brenchley PE. Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int. 2017;91(1):76-89. doi:10.1016/j.kint.2016.08.003

3. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21. doi:10.1056/NEJMoa0810457

4. Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet. 2015;385(9981):1983-1992. doi:10.1016/S0140-6736(15)60731-0

5. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277-2287. doi:10.1056/NEJMoa1409354

6. Polanco N, Gutierrez E, Covarsi A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697-704. doi:10.1681/ASN.2009080861

7. Lefaucheur C, Stengel B, Nochy D, et al. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int. 2006;70(8):1510-1517. doi:10.1038/sj.ki.5001790

8. Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med. 2011;364(7):616-626. doi:10.1056/NEJMoa1009742

9. Seitz-Polski B, Dolla G, Payre C, et al. Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy. J Am Soc Nephrol. 2016;27(5):1517-1533. doi:10.1681/ASN.2014111061

10. Sethi S, Debiec H, Engel A, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 2020;97(1):163-174. doi:10.1016/j.kint.2019.09.014

11. Lionaki S, Derebail VK, Hogan SL, et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol. 2012;7(1):43-51. doi:10.2215/CJN.04250511

12. Hoxha E, Thiele I, Zahner G, et al. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. 2014;25(6):1357-1366. doi:10.1681/ASN.2013070714

13. Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019;381(1):36-46. doi:10.1056/NEJMoa1814427

14. Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 1995;48(5):1600-1604. doi:10.1038/ki.1995.452

15. Sprangers B, Lefkowitz GI, Cohen SD, et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol. 2010;5(5):790-797. doi:10.2215/CJN.04120609

16. Dahan K, Debiec H, Plaisier E, et al. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial With Extended Follow-Up. J Am Soc Nephrol. 2017;28(1):348-358. doi:10.1681/ASN.2016040449

17. De Vriese AS, Glassock RJ, Nath KA, et al. A Proposal for a Serology-Based Approach to Membranous Nephropathy. J Am Soc Nephrol. 2017;28(2):421-430. doi:10.1681/ASN.2016070776

18. Floege J, Amann K. Primary glomerulonephritides. Lancet. 2016;387(10032):2036-2048. doi:10.1016/S0140-6736(16)00272-5

19. van de Logt AE, Hofstra JM, Wetzels JF. Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up. Kidney Int. 2015;87(6):1263-1264. doi:10.1038/ki.2015.34

20. Ruggenenti P, Debiec H, Ruber B, et al. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. J Am Soc Nephrol. 2015;26(10):2545-2558. doi:10.1681/ASN.2014070640